US-Chi­na ten­sions per­sist; Gen­mab's $1.8B ADC bet; New obe­si­ty start­up in town; ALS drug with­draw­al; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

We have a busy week­end ahead of us, with the an­nu­al con­fer­ences of both the Amer­i­can As­so­ci­a­tion for Can­cer Re­search and the Amer­i­can Col­lege of Car­di­ol­o­gy in full swing. Be sure to check in on Mon­day for our cov­er­age of the lat­est clin­i­cal da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER